iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. iRhythm Technologies, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
IPO Year: 2016
Exchange: NASDAQ
Website: irhythmtech.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/5/2026 | $210.00 | In-line → Outperform | Evercore ISI |
| 9/23/2025 | $185.00 | In-line | Evercore ISI |
| 8/20/2025 | $200.00 | Buy | BofA Securities |
| 5/2/2025 | $130.00 | Equal Weight → Overweight | Wells Fargo |
| 12/3/2024 | $86.00 | Equal Weight | Wells Fargo |
| 10/4/2024 | $78.00 | Neutral | Goldman |
| 6/20/2024 | $115.00 | Peer Perform → Outperform | Wolfe Research |
| 12/11/2023 | $110.00 | Neutral → Buy | Citigroup |
| 7/19/2023 | $130.00 | Outperform | Robert W. Baird |
| 2/7/2023 | $150.00 | Overweight | Wells Fargo |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - iRhythm Holdings, Inc. (0001388658) (Issuer)
4 - iRhythm Holdings, Inc. (0001388658) (Issuer)
4 - iRhythm Holdings, Inc. (0001388658) (Issuer)
4 - iRhythm Holdings, Inc. (0001388658) (Issuer)
4 - iRhythm Holdings, Inc. (0001388658) (Issuer)
4 - iRhythm Holdings, Inc. (0001388658) (Issuer)
4 - iRhythm Holdings, Inc. (0001388658) (Issuer)
4 - iRhythm Holdings, Inc. (0001388658) (Issuer)
4 - iRhythm Holdings, Inc. (0001388658) (Issuer)
4 - iRhythm Holdings, Inc. (0001388658) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Evercore ISI upgraded iRhythm from In-line to Outperform and set a new price target of $210.00
Evercore ISI initiated coverage of iRhythm with a rating of In-line and set a new price target of $185.00
BofA Securities initiated coverage of iRhythm with a rating of Buy and set a new price target of $200.00
Wells Fargo upgraded iRhythm from Equal Weight to Overweight and set a new price target of $130.00
Wells Fargo resumed coverage of iRhythm with a rating of Equal Weight and set a new price target of $86.00
Goldman initiated coverage of iRhythm with a rating of Neutral and set a new price target of $78.00
Wolfe Research upgraded iRhythm from Peer Perform to Outperform and set a new price target of $115.00
Citigroup upgraded iRhythm from Neutral to Buy and set a new price target of $110.00
Robert W. Baird initiated coverage of iRhythm with a rating of Outperform and set a new price target of $130.00
Wells Fargo initiated coverage of iRhythm with a rating of Overweight and set a new price target of $150.00
Fastest customizable press release news feed in the world
SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that the company will be participating in the following investor conferences. William Blair 46th Annual Growth Stock Conference on June 2, 2026, at 8:00 a.m. CT (6:00 a.m. PT)Truist Securities MedTech Conference on June 16, 2026, at 2:20 p.m. ET (11:20 a.m. PT) Interested parties may access a live and archived webcast of the presentation on the "Events & Presentations" section of the company's investor website at investors.irhythmtech.com. About iRhythm Holdings, Inc. i
SAN FRANCISCO, April 30, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2026. First Quarter 2026 Financial Highlights Revenue of $199.4 million, a 25.7% increase compared to first quarter 2025Gross margin of 70.9%, a 210-basis point increase compared to first quarter 2025Net loss of $13.9 million, a $16.8 million improvement compared to first quarter 2025Adjusted EBITDA and adjusted EBITDA margin of $14.1 million and 7.1%, respectively, a $16.7 million and 880-basis point improvement, r
SAN FRANCISCO, April 28, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced the company will be participating in the upcoming Bank of America Securities 2026 Health Care Conference. iRhythm's management is scheduled to present on Wednesday, May 13, 2026, 9:20 a.m. Pacific Time/12:20 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Events & Presentations" section of the company's investor website at investors.irhythmtech.com. About iRhythm Holdings, Inc. iRhythm is a leading digital health
Real-world data presented at HRS 2026 add to the body of evidence supporting a shift away from short-duration Holter monitoring toward up to 14 days of continuous, uninterrupted monitoring with Zio® ambulatory ECG devices to reduce missed arrhythmias and provide a more complete assessment of arrhythmia burden, including in post-ablation and pregnancy populations.1-2Findings raise important considerations for post-ablation anticoagulation decisions based on prior studies such as the OCEAN trial that relied on short-duration (24–48-hour) monitoring, as these data show this approach would miss AF recurrence in 26% of patients.1 SAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdin
SAN FRANCISCO, April 16, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the first quarter 2026 after the close of trading on Thursday, April 30, 2026. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the conference call on the "Quarterly Results" section of the company's investor website at investors.irhythmtech.com. About iRhythm Holdings, Inc. iRhythm is a leading digital
Data presented at ACC.26 demonstrate a high prevalence of clinically actionable arrhythmias across CKM patient populations using the Zio® ambulatory ECG portfolio.1,2Chief Medical Officer Mintu Turakhia, MD, MS, delivered the 57th Annual Louis F. Bishop Keynote on scaling AI in cardiology and translating advances into clinical practice.iRhythm Academy launch expands access to clinician education at scale in ambulatory cardiac monitoring as the field continues to advance. SAN FRANCISCO, March 30, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC) announced results from three retrospective analyses presented at the American College of Cardiology (ACC) 2026 Annual Scientific Sessi
SAN FRANCISCO, March 12, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, is pleased to announce the appointment of Jason Patten to its Board of Directors, effective March 12, 2026. Mr. Patten brings decades of strategic leadership in healthcare, reinforcing iRhythm's commitment to innovation, operational excellence, and long-term growth. "We are thrilled to welcome Jason Patten to our Board of Directors at an important moment in iRhythm's evolution," said Abhi Talwalkar, Chairman of the Board of Directors. "As we scale and expand profitability, we are focus
SAN FRANCISCO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights Revenue of $208.9 million, a 27.1% increase compared to fourth quarter 2024Gross margin of 70.9%, a 90-basis point increase compared to fourth quarter 2024Net income of $5.6 million, a $6.9 million improvement compared to fourth quarter 2024 and the first quarter of positive GAAP net income in Company historyAdjusted EBITDA and adjusted EBITDA margin of
SAN FRANCISCO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the fourth quarter and full year 2025 after the close of trading on Thursday, February 19, 2026. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the conference call on the "Quarterly Results" section of the company's investor website at investors.irhythmtech.com. About iRhythm Holdings, Inc. iRhythm is
SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced preliminary fourth quarter operational highlights and a business update at the 44th Annual J.P. Morgan Healthcare Conference. Recent Operational Highlights and Financial Outlook Anticipate full year 2025 revenue to exceed high end of previously stated guidance range of $740 million provided in October 2025, driven by record revenue unit volume during the fourth quarter 2025For full year 2026, expect revenue of approximately $870 million to $880 million, or approximat
8-K - iRhythm Holdings, Inc. (0001388658) (Filer)
S-8 - iRhythm Holdings, Inc. (0001388658) (Filer)
144 - iRhythm Holdings, Inc. (0001388658) (Subject)
SCHEDULE 13G/A - iRhythm Holdings, Inc. (0001388658) (Subject)
10-Q - iRhythm Holdings, Inc. (0001388658) (Filer)
8-K - iRhythm Holdings, Inc. (0001388658) (Filer)
DEFA14A - iRhythm Holdings, Inc. (0001388658) (Filer)
DEF 14A - iRhythm Holdings, Inc. (0001388658) (Filer)
PRE 14A - iRhythm Holdings, Inc. (0001388658) (Filer)
8-K - iRhythm Holdings, Inc. (0001388658) (Filer)
Live Leadership Updates
SAN FRANCISCO, March 12, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, is pleased to announce the appointment of Jason Patten to its Board of Directors, effective March 12, 2026. Mr. Patten brings decades of strategic leadership in healthcare, reinforcing iRhythm's commitment to innovation, operational excellence, and long-term growth. "We are thrilled to welcome Jason Patten to our Board of Directors at an important moment in iRhythm's evolution," said Abhi Talwalkar, Chairman of the Board of Directors. "As we scale and expand profitability, we are focus
iRhythm is the first medical device company to join the Epic community, using Aura to drive efficiencies through EHR integrationThe collaboration will expand access to Zio service across the continuum of patient care—from cardiology to primary care to emergency departments and beyond1 SAN FRANCISCO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare company focused on creating trusted solutions that detect, predict, and prevent disease, today announced it will use Epic's Aura platform to streamline access to iRhythm's Zio long-term continuous monitoring and ambulatory mobile cardiac telemetry services ("Zio services") through improved
A seasoned leader, Sung brings deep finance, capital markets, and strategy experience across the medical device industry Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, announced today that Derrick Sung has been appointed chief financial officer of the company. Sung brings over 25 years of finance, capital markets, and strategy experience across diverse roles within the medical device industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231120576987/en/Derrick Sung has been appointed chief financial officer
SAN FRANCISCO, June 06, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the appointment of Mojdeh Poul and Brian Yoor as directors to its Board effective June 1, 2023. "On behalf of the entire iRhythm team, I am thrilled to welcome Mojdeh and Brian to our Board of Directors," said Quentin Blackford, iRhythm's President and CEO. "Both bring extensive operational experience, strong financial acumen, and public company leadership across the global healthcare and medical technology sectors. We believe their proven track record of delivering
SAN FRANCISCO, July 25, 2022 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced the appointment of two seasoned executives to its leadership team. Brice Bobzien will join the company as the Chief Financial Officer on August 8, 2022, to lead all financial operations of the company as well as to advance the culture of operational excellence and prepare the company for future growth. Reyna Fernandez will join as the company's Executive Vice President, Chief Human Resources Officer on July 25, 2022, to lead the development and implementation of human resources strategies in sup
SAN FRANCISCO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) ("iRhythm"), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced the appointment of Karen Ling, an experienced HR leader, to its Board of Directors effective November 1, 2021. Ms. Ling was appointed as a Class 1 Director. The company also announced the retirement of Raymond Scott from the Board, effective November 1, 2021. Mr. Scott joined the iRhythm Board in 2013. "On behalf of the entire iRhythm team, I am pleased to welcome Karen to our Board of Directors," said Quentin Blackford, iRhythm President and CEO. "Karen is a renowned HR leader in t
SAN FRANCISCO, Dec. 14, 2020 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced that Kevin King will retire as President and CEO effective January 12, 2021. Mr. King will continue to serve on iRhythm's board of directors and as an advisor to the business. Effective the same date, Mike Coyle will join the company as President and CEO and as a member of its board of directors. Under King’s leadership, iRhythm successfully completed an IPO in 2016, achieved record financial growth and increased shareholder value significantly. During his tenure, the company’s annual revenue
This live feed shows all institutional transactions in real time.
SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)
SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)
SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)
SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)
SC 13G - iRhythm Technologies, Inc. (0001388658) (Subject)
SC 13G - iRhythm Technologies, Inc. (0001388658) (Subject)
SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)
SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)
SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)
SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)
Live finance-specific insights
SAN FRANCISCO, April 30, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2026. First Quarter 2026 Financial Highlights Revenue of $199.4 million, a 25.7% increase compared to first quarter 2025Gross margin of 70.9%, a 210-basis point increase compared to first quarter 2025Net loss of $13.9 million, a $16.8 million improvement compared to first quarter 2025Adjusted EBITDA and adjusted EBITDA margin of $14.1 million and 7.1%, respectively, a $16.7 million and 880-basis point improvement, r
SAN FRANCISCO, April 16, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the first quarter 2026 after the close of trading on Thursday, April 30, 2026. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the conference call on the "Quarterly Results" section of the company's investor website at investors.irhythmtech.com. About iRhythm Holdings, Inc. iRhythm is a leading digital
SAN FRANCISCO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights Revenue of $208.9 million, a 27.1% increase compared to fourth quarter 2024Gross margin of 70.9%, a 90-basis point increase compared to fourth quarter 2024Net income of $5.6 million, a $6.9 million improvement compared to fourth quarter 2024 and the first quarter of positive GAAP net income in Company historyAdjusted EBITDA and adjusted EBITDA margin of
SAN FRANCISCO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the fourth quarter and full year 2025 after the close of trading on Thursday, February 19, 2026. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the conference call on the "Quarterly Results" section of the company's investor website at investors.irhythmtech.com. About iRhythm Holdings, Inc. iRhythm is
SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended September 30, 2025. Third Quarter 2025 Financial Highlights Revenue of $192.9 million, a 30.7% increase compared to third quarter 2024Gross margin of 71.1%, a 230-basis point increase compared to third quarter 2024Unrestricted cash, cash equivalents, and marketable securities of $565.2 million as of September 30, 2025Increased fiscal year 2025 guidance for revenue and adjusted EBITDA margin Recent Operational Highlights
SAN FRANCISCO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the third quarter 2025 after the close of trading on Thursday, October 30, 2025. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the conference call on the "Quarterly Results" section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc. iRhythm is a leadin
SAN FRANCISCO, July 31, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended June 30, 2025. Second Quarter 2025 Financial Highlights Revenue of $186.7 million, a 26.1% increase compared to second quarter 2024Gross margin of 71.2%, a 130-basis point increase compared to second quarter 2024Unrestricted cash, cash equivalents, and marketable securities of $545.5 million as of June 30, 2025Increased fiscal year 2025 guidance for revenue and adjusted EBITDA Recent Operational Highlights
SAN FRANCISCO, July 17, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the second quarter 2025 after the close of trading on Thursday, July 31, 2025. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the conference call on the "Quarterly Results" section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc. iRhythm is a leading
SAN FRANCISCO, May 01, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2025. First Quarter 2025 Financial Highlights Revenue of $158.7 million, a 20.3% increase compared to first quarter 2024Gross margin of 68.8%, a 250-basis point increase compared to first quarter 2024Unrestricted cash, cash equivalents, and marketable securities of $520.6 million as of March 31, 2025Increased fiscal year 2025 guidance for revenue and adjusted EBITDA margin Recent Operational Highlights Strong qu
SAN FRANCISCO, April 17, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the first quarter 2025 after the close of trading on Thursday, May 1, 2025. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the conference call on the "Quarterly Results" section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc. iRhythm is a leading di
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - iRhythm Holdings, Inc. (0001388658) (Issuer)
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4/A - iRhythm Technologies, Inc. (0001388658) (Issuer)